Company Description

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System.

The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.

It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room.

LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR, Inc.

Country	United States
Founded	2004
Industry	Medical Devices
Sector	Healthcare
Employees	140
CEO	Nicholas Curtis

Contact Details

Address: 2800 Discovery Drive Orlando, Florida 32826 United States
Phone	888 536 7271
Website	lensar.com

Stock Details

Ticker Symbol	LNSR
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001320350
CUSIP Number	52634L108
ISIN Number	US52634L1089
Employer ID	32-0125724
SIC Code	3841

Key Executives

Name	Position
Nicholas T. Curtis	President, Chief Executive Officer and Director
Thomas R. Staab II, CPA	Chief Financial Officer and Secretary
Alan B. Connaughton	Chief Operating Officer
Kendra W. Wong	Principal Accounting Officer

Latest SEC Filings

Date	Type	Title
Nov 13, 2025	SCHEDULE 13G	Filing
Nov 6, 2025	10-Q	Quarterly Report
Nov 6, 2025	8-K	Current Report
Nov 5, 2025	ARS	Filing
Nov 5, 2025	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 5, 2025	DEF 14A	Other definitive proxy statements
Oct 21, 2025	8-K	Current Report
Oct 17, 2025	SCHEDULE 13G	Filing
Aug 7, 2025	10-Q	Quarterly Report
Aug 7, 2025	8-K	Current Report

View All SEC Filings